{"id":"NCT00556712","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of Tarceva (Erlotinib) Following Platinum-Based Chemotherapy in Patients With Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer (NSCLC)","officialTitle":"A Randomized, Double-blind Study to Evaluate the Effect of Tarceva or Placebo Following Platinum-based CT on Overall Survival and Disease Progression in Patients With Advanced, Recurrent or Metastatic NSCLS Who Have Not Experienced Disease Progression or Unacceptable Toxicity During Chemotherapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-01","primaryCompletion":"2010-11","completion":"2010-11","firstPosted":"2007-11-12","resultsPosted":"2015-02-11","lastUpdate":"2015-02-11"},"enrollment":889,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Non-Small Cell Lung Cancer"],"interventions":[{"type":"DRUG","name":"erlotinib [Tarceva]","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Erlotinib","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This 2 arm study will evaluate the efficacy, safety, and pharmacokinetics of Tarceva, compared with placebo, following platinum-based chemotherapy in patients with advanced, recurrent, or metastatic NSCLC who have not had disease progression or unacceptable toxicity during chemotherapy. Following 4 cycles of platinum-based chemotherapy, eligible patients will be randomized to receive either Tarceva 150mg po daily, or placebo daily. The anticipated time on study treatment is until disease progression; the target sample size is 500+ individuals.","primaryOutcome":{"measure":"Percentage of Participants With PD According to Response Evaluation Criteria in Solid Tumors (RECIST) or Death (Data Cutoff 17 May 2008)","timeFrame":"Screening, BL [â‰¤21 days after randomization], every 6 weeks thereafter until Week 48, every 12 weeks thereafter until PD, discontinuation of study treatment, or end of survival follow-up, up to data cutoff of 17 May 2008 (up to 27 months)","effectByArm":[{"arm":"Placebo","deltaMin":89.5,"sd":null},{"arm":"Erlotinib, 150 mg/Day","deltaMin":79.9,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":2},"locations":{"siteCount":133,"countries":["Australia","Austria","Belgium","Canada","Chile","China","Czechia","Denmark","France","Germany","Greece","Hungary","Italy","Lithuania","Malaysia","Netherlands","New Zealand","Poland","Romania","Russia","Slovakia","Slovenia","South Africa","South Korea","Spain","Ukraine","United Kingdom","Venezuela"]},"refs":{"pmids":["20493771"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":445},"commonTop":["Rash","Diarrhoea","Cough","Dyspnoea","Fatigue"]}}